{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T21:22:07Z","timestamp":1772659327839,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"HELIOS Universit\u00e4tsklinikum Wuppertal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Seit der Markteinf\u00fchrung der COVID-19-Impfstoffe werden regelm\u00e4\u00dfig kutane Nebenwirkungen dieser Vakzine beschrieben. Diese beinhalten unter anderem lokale Impfreaktionen (insbesondere den sog. COVID-Arm), urtikarielle, makulopapul\u00f6se und pityriasiforme Exantheme oder vor\u00fcbergehende Exazerbationen einer vorbestehenden chronisch entz\u00fcndlichen Hauterkrankung. Wir berichten \u00fcber 3\u00a0F\u00e4lle einer Pityriasis rubra pilaris, die in engem zeitlichen Zusammenhang mit der Verabreichung eines COVID-19-Impfstoffs erstmals aufgetreten sind.<\/jats:p>","DOI":"10.1007\/s00105-022-04972-z","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T17:04:35Z","timestamp":1647450275000},"page":"634-637","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pityriasis rubra pilaris nach COVID-19-Impfung: Kausaler Zusammenhang oder Koinzidenz?","Pityriasis rubra pilaris after COVID-19 vaccination: causal relationship or coincidence?"],"prefix":"10.1007","volume":"73","author":[{"given":"A. C.","family":"Bramhoff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Wesselmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. T.","family":"Bender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. V.","family":"Berghoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. C.","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Balakirski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"issue":"27","key":"4972_CR1","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack\u00a0FP, Thomas\u00a0SJ, Kitchin\u00a0N et al (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N\u00a0Engl J Med 383(27):2603\u20132615","journal-title":"N Engl J Med"},{"issue":"13","key":"4972_CR2","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMc2102131","volume":"384","author":"KG Blumenthal","year":"2021","unstructured":"Blumenthal\u00a0KG, Freeman\u00a0EE, Saff\u00a0RR et al (2021) Delayed large local reactions to mRNA-1273 vaccine against SARSCoV\u20112. N\u00a0Engl J Med 384(13):1273\u20131277","journal-title":"N Engl J Med"},{"issue":"1","key":"4972_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/ced.14858","volume":"47","author":"A Kreuter","year":"2022","unstructured":"Kreuter\u00a0A, Licciardi-Fernandez\u00a0MJ, Burmann\u00a0SN et\u00a0al (2022) Induction and exacerbation of subacute cutaneous lupus erythematosus following mRNA-based or adenoviral vector-based SARS-CoV\u20112 vaccination. Clin Exp Dermatol 47(1):161\u2013163. https:\/\/doi.org\/10.1111\/ced.14858","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"4972_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2021.03.092","volume":"85","author":"DE McMahon","year":"2021","unstructured":"McMahon\u00a0DE, Amerson\u00a0E, Rosenbach\u00a0M et al (2021) Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414\u00a0cases. J\u00a0Am Acad Dermatol 85(1):46\u201355","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"4972_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jaad.2021.09.002","volume":"86","author":"DE McMahon","year":"2022","unstructured":"McMahon\u00a0DE, Kovarik\u00a0CL, Damsky\u00a0W et\u00a0al (2022) Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V\u2011REPP: a\u00a0registry based study. J\u00a0Am Acad Dermatol 86(1):113\u2013121. https:\/\/doi.org\/10.1016\/j.jaad.2021.09.002","journal-title":"Am Acad Dermatol"},{"issue":"4","key":"4972_CR6","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.jaad.2020.07.052","volume":"84","author":"A Mufti","year":"2021","unstructured":"Mufti\u00a0A, Lytvyn\u00a0Y, Maliyar\u00a0K, Sachdeva\u00a0M, Yeung\u00a0J (2021) Drugs associated with development of pityriasis rubra pilaris: a systematic review. J\u00a0Am Acad Dermatol 84(4):1071\u20131081","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"4972_CR7","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1001\/jamadermatol.2020.3426","volume":"156","author":"K Halper","year":"2020","unstructured":"Halper\u00a0K, Wright\u00a0B, Maloney\u00a0NJ et\u00a0al (2020) Characterizing disease features and other medical diagnoses in patients with pityriasis rubra pilaris. JAMA Dermatol 156(12):1373\u20131374","journal-title":"JAMA Dermatol"},{"issue":"10","key":"4972_CR8","doi-asserted-by":"publisher","first-page":"e622","DOI":"10.1111\/jdv.17424","volume":"35","author":"D Kadylak","year":"2021","unstructured":"Kadylak\u00a0D, Bara\u0144ska-Rybak\u00a0W (2021) Acute postinfectious pityriasis rubra pilaris as a\u00a0cutaneous manifestation in COVID-19: a\u00a0case report and its dermoscopic features. J\u00a0Eur Acad Dermatol Venereol 35(10):e622\u2013e624. https:\/\/doi.org\/10.1111\/jdv.17424","journal-title":"Eur"},{"issue":"4","key":"4972_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3233\/JRS-210048","volume":"32","author":"MK Sahni","year":"2021","unstructured":"Sahni\u00a0MK, Roy\u00a0K, Asati\u00a0DP, Khurana\u00a0U (2021) An old entity, a\u00a0new trigger: post COVID-19 vaccine pityriasis rubra pilaris. Int J Risk Saf Med 32(4):261\u2013264. https:\/\/doi.org\/10.3233\/JRS-210048","journal-title":"Int J Risk Saf Med"},{"issue":"12","key":"4972_CR10","doi-asserted-by":"publisher","first-page":"e833","DOI":"10.1111\/jdv.17542","volume":"35","author":"I Llad\u00f3","year":"2021","unstructured":"Llad\u00f3\u00a0I, Butr\u00f3n\u00a0B, Sampedro-Ruiz\u00a0R, Fraga\u00a0J, de Argila\u00a0D (2021) Pityriasis rubra pilaris after Vaxzevria\u00ae COVID-19 vaccine. J\u00a0Eur Acad Dermatol Venereol 35(12):e833\u2013e835. https:\/\/doi.org\/10.1111\/jdv.17542","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"4972_CR11","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/ced.14878","volume":"47","author":"MK Hunjan","year":"2022","unstructured":"Hunjan\u00a0MK, Roberts\u00a0C, Karim\u00a0S, Hague\u00a0J (2022) Pityriasis rubra pilaris like eruption following administration of the BNT163b2 (Pfizer BioNTech) mRNA COVID-19 vaccine. Clin Exp Dermatol 47(1):188\u2013190. https:\/\/doi.org\/10.1111\/ced.14878","journal-title":"Clin Exp Dermatol"},{"key":"4972_CR12","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.3389\/fimmu.2019.01918","volume":"10","author":"R Speeckaert","year":"2019","unstructured":"Speeckaert\u00a0R, Lambert\u00a0J, van Geel\u00a0N (2019) Learning from success and failure: biologics for non-approved skin diseases. Front Immunol 10:1918","journal-title":"Front Immunol"},{"issue":"2","key":"4972_CR13","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","volume":"27","author":"KJ Ewer","year":"2021","unstructured":"Ewer\u00a0KJ, Barrett\u00a0JR, Belij-Rammerstorfer\u00a0S et al (2021) T cell and antibody responses induced by a\u00a0single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a\u00a0phase 1\/2 clinical trial. Nat Med 27(2):270\u2013278","journal-title":"Nat Med"},{"issue":"5","key":"4972_CR14","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1684\/ejd.2020.3879","volume":"30","author":"C Kromer","year":"2020","unstructured":"Kromer\u00a0C, Lippert\u00a0U, Sch\u00f6n\u00a0MP, M\u00f6ssner\u00a0R (2020) Treatment of pityriasis rubra pilaris: a\u00a0case series of 28\u00a0patients. Eur J Dermatol 30(5):569\u2013579","journal-title":"Eur J Dermatol"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-022-04972-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-022-04972-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-022-04972-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T22:17:12Z","timestamp":1658960232000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-022-04972-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,16]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["4972"],"URL":"https:\/\/doi.org\/10.1007\/s00105-022-04972-z","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,16]]},"assertion":[{"value":"14 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.C.\u00a0Bramhoff, U.\u00a0Wesselmann, S.T.\u00a0Bender, A.V.\u00a0Berghoff, S.C.\u00a0Hofmann und G.\u00a0Balakirski geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}